Optoderma takes on global psoriasis
This article was originally published in The Rose Sheet
Executive Summary
Company's products for the treatment of psoriasis will be available in the U.S., Canada and Mexico at the end of the month, it announces Nov. 21. Distribution in the U.S. will follow FDA registration as an over-the-counter drug. Optoderma also will expand to 21 countries in the Middle East around the same time through a distribution agreement with a United Arab Emirates company, firm adds. "Highly effective" Optoderma - which comes in cream, lotion and gel form for various applications - is currently sold throughout Europe, as well as online. In Germany, the product's turnover quintupled between January and September of this year, firm adds...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.